Actualités TuHURA Biosciences Inc - HURA | Actions NASDAQ

Dow Jones

40 227,59

0,28%

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
Actions
Etats-Unis
NASDAQ
TuHURA Biosciences Inc (HURA)
TuHURA Biosciences Inc (HURA) Actualités

TuHURA Biosciences Inc (HURA)

3,97

-0,13

(-3,17%)

À la fermeture: 29 Avril 10:00PM

Retardé de 15 minutes

3,97

0,00

( 0,00% )

Après les heures de négociation: 10:30PM

Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeti

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's...

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual...

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug...

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update PR...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Ravenquest Biomed (CE)

ProShares UltraPro S&P 500

iShares US Equity Factor...

DJ Global Middle East & ...

AMEX

INCM

Franklin Income Focus ETF

AMEX

WLDR

Affinity World Leaders E...

Vontobel Financial Produ...

NASDAQ

FAWRX

Agf American Growth Clas...

NYSE

ELAN

Elanco Animal Health

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

TuHURA Biosciences Inc (HURA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

HURA Actualités

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeti

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

TuHURA Biosciences Inc (HURA) Actualités

TuHURA Biosciences Inc (HURA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

HURA Actualités

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeti

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Abonnez-vous à un compte ADVFN en remplissant le formulaire ci-dessous!

Supprimer les publicités